key: cord-1010879-4w03utdv
authors: Aiyegbusi, Olalekan Lee; Nair, Devika; Peipert, John Devin; Schick-Makaroff, Kara; Mucsi, Istvan
title: A narrative review of current evidence supporting the implementation of electronic patient-reported outcome measures in the management of chronic diseases
date: 2021-05-24
journal: Ther Adv Chronic Dis
DOI: 10.1177/20406223211015958
sha: 86a400259105a567ee9b86d250a33ee01557b22c
doc_id: 1010879
cord_uid: 4w03utdv

An application of telemedicine of growing interest and relevance is the use of personal computers and mobile devices to collect patient-reported outcomes (PROs). PROs are self-reports of patients’ health status without interpretation by anyone else. The tools developed to assess PROs are known as patient-reported outcomes measures (PROMs). The technological innovations that have led to an increased ownership of electronic devices have also facilitated the development of electronic PROMs (ePROMs). ePROMs are a conduit for telemedicine in the care of patients with chronic diseases. Various studies have demonstrated that the use of ePROMs in routine clinical practice is both acceptable and feasible with patients increasingly expressing a preference for an electronic mode of administration. There is increasing evidence that the use of electronic patient-reported outcome (ePROMs) could have significant impacts on outcomes valued by patients, healthcare providers and researchers. Whilst the development and implementation of these systems may be initially costly and resource-intensive, patient preferences and existing evidence to support their implementation suggests the need for continued research prioritisation in this area. This narrative review summarises and discusses evidence of the impact of ePROMs on clinical parameters and outcomes relevant to chronic diseases. We also explore recently published literature regarding issues that may influence the robust implementation of ePROMs for routine clinical practice.

Telemedicine refers to the use of electronic information and communications technology to provide and support healthcare remotely. 1, 2 An application of telemedicine of growing interest and relevance is the use of personal computers and mobile devices to collect patient-reported outcomes (PROs). 3 PROs are self-reports of patients' health status without interpretation by anyone else. 4 The tools developed to assess PROs are known as patient-reported outcomes measures (PROMs).

Although the use of PROMs in clinical trials to assess the impact of interventions is well established, interest in their use in routine clinical practice is on the increase. The technological innovations that led to an increased ownership of electronic devices have also facilitated the development of electronic PROMs (ePROMs). 5 PROMs are traditionally paper-based while the term 'ePROMs' refers to telephone-based interactive voice response systems and screen-based systems. 6 ePROMs may be administered at clinic, with or without clinical supervision, or remotely in an unsupervised setting (such as subject's home or workplace). Remote assessment enables more timely and accurate self-reporting and may avoid potential recall bias. 6 The National Centre for Chronic Disease Prevention and Health Promotion (NCCDPHP) defined chronic diseases as conditions that last a year or more and require ongoing medical attention or limit activities of daily living or both. 7 The definition encompasses conditions such as heart diseases, cancer, chronic lung disease, stroke, Alzheimer's disease, diabetes and chronic kidney disease (CKD). Most of these diseases are presently incurable. Patients with chronic diseases often require long-term care while experiencing significant symptom burden, which may impair their health-related quality of life (HR-QOL). 8 The use of ePROMs provides patients the opportunity to report remotely the impact of disease and treatment on their HR-QOL. Such information may inform the clinical management of patients. Various studies have demonstrated that the use of ePROMs in routine clinical practice is both acceptable and feasible, with patients increasingly expressing a preference for an electronic mode of administration. 9, 10 However, despite these advancements, doubts about the quantifiable benefits of implementing PROMs/ePROMs for use in routine clinical practice persist and there are still concerns around integration with existing workflows. [11] [12] [13] Whilst the potential impact of PROMs/ePROMs on patientclinician communication has been well documented, [14] [15] [16] their impact on patient outcomes or clinical parameters has been limited. 17, 18 A systematic review by Boyce and Browne found weak evidence that provision of PROM data to healthcare professionals resulted in a positive impact on patient outcomes. 19 The review also reported that studies that demonstrated the most significant impact used PROMs to facilitate patient care in an outpatient setting and there was weak evidence supporting their use as a screening tool. 19 The review included commentaries, editorials, systematic reviews and a limited number of primary studies.

The majority of the relevant primary studies available at the time of Boyce and Browne's review reported PROM projects in their nascent stages. [20] [21] [22] [23] [24] These studies were mostly crosssectional, feasibility or pilot studies, which are not designed to capture the impact of PROM data on patient outcomes. Furthermore, these studies were conducted prior to the publication of PRO-specific clinical trial guidelines such as the SPIRIT-PRO (Standard Protocol Items: Recommendations for Interventional Trials-PRO Extension) to facilitate the incorporation of PROs into clinical trial protocols and the CONSORT-PRO (Consolidated Standards of Reporting Trials-PRO Extension) to guide the reporting of PROM data from clinical trials. 25, 26 Since the publication of the Boyce and Browne review in 2013, an increasing number of high quality, longitudinal studies aimed at measuring the impact of ePROMs on clinical outcomes have been reported. 27, 28 This review aimed to summarise and discuss evidence of the impact of ePROMs on clinical outcomes relevant to the management of chronic diseases as defined by the NCCDPHP. We also explored recently published literature regarding issues that may influence the robust implementation of ePROMs for routine clinical practice. We focus on articles published since the Boyce and Browne 2013 review.

Prior to conducting this review, the authors were aware of the two highly cited articles by Basch et al. that reported compelling evidence of the impact of ePROMs on clinical outcomes since the publication of the Boyce and Brown review. 19, 28, 29 Forward citation searches of these three articles on the Web of Science (WoS) database (All Databases version) were conducted by OLA on 12 September 2020. 19, 28, 29 This approach facilitated the efficient retrieval of recent and relevant articles. In addition, Google Scholar was searched on 12 February 2021 to ensure that all relevant and recent articles were captured.

Titles and abstracts were screened for relevance and full-text articles were obtained for articles that potentially met the eligibility criteria. journals.sagepub.com/home/taj 3

Randomised controlled trials (RCTs), cohort studies and observational studies of any chronic disease were included if they reported the impact of ePROMs on clinical outcomes and/or healthcare resource use in chronic disease care. Specifically, our outcomes of interest included: patient survival, symptom management, treatment adherence and utilisation of healthcare resources. There were no language restrictions.

Articles were excluded if they reported: (i) studies relating to PROMs administered in paper form;

(ii) clinician-reported instruments; (iii) pilot studies that only detailed the feasibility or acceptability of ePROMs or impacts on patient-clinician communications; and (iv); editorials, reviews, and conference abstracts.

The included studies were appraised using the appropriate critical appraisal skills programme (CASP) checklists. 30

The search on WoS retrieved 1099 entries for title and abstract screening. The full-texts for 52 were obtained for further review and 16 articles selected. Table 1 summarises the characteristics and findings of the included articles. Most of the articles reporting the impact of ePROMs on clinical parameters and outcomes in chronic conditions were derived from oncology. A few focussed on diseases such as rheumatoid arthritis, epilepsy and sleep apnoea. 27, 31 All except one study were conducted in outpatient settings and most were RCTs. 32 There was evidence that the use of ePROMs in routine clinical practice may improve patient survival, symptom management and individualised care, treatment adherence; encourage efficient utilisation of healthcare resources; and reduce risk of disease transmission during outbreaks and epidemics. A critical appraisal of the studies was conducted and the findings summarised in Table 2 .

Evidence to support the use of ePROMs in routine clinical care

Improved patient survival A single-centre RCT by Basch et al. in the United States (US) reported statistically significant associations between the use of the 'STAR' (Symptom Tracking and Reporting) system, a web-based ePROM interface for telemonitoring, and patient survival following chemotherapy for advanced solid tumours. 28 The system incorporates 'patient-adapted questions' from the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) checklist. 44 It was not clear from the article whether these questions were derived from CTCAE items or the patient-specific PRO-CTCAE. 45 At 1 year after the start of the intervention, patients in the intervention arm, whose symptoms were monitored using STAR, experienced a significant survival advantage over those in the control arm who received routine surveillance. 28 Email reminders were sent to patients randomised to the STAR group and nurses initiated clinical response to alerts generated by patients using the STAR system (see Table 1 ). The effect of the intervention on survival was greater among participants who had less computer experience, and who were more likely to be older, male, black and less educated. 28 In an assessment of overall survival, conducted after a median follow-up of 7 years, patients in the STAR arm experienced a statistically significant survival advantage of 5 months over patients in the usual care arm. 29 In a multicentre study conducted in France by Denis et al. that further tested the approaches employed by Basch et al., patients with advanced lung cancer following initial treatment were randomly assigned to receive either web-based symptom monitoring via an ePROM system (Hyperion) or standard follow up (scheduled imaging). 35 Interim analysis at 9 months showed that patients in the ePROM group experienced a survival benefit of 7 months. This led to the decision by the independent data monitoring committee to mandate the crossover of patients in the control to the intervention arm. Furthermore, the overall survival rate at 1 year was significantly higher in the ePROM arm than in the control arm (74.9% versus 48.5%). 35 These results were attributed to earlier detection of lung cancer relapse in the ePROM group. In addition, as the ePROM system was reliable in detecting patient relapse, a 49% reduction in CT scans was reported for patients in the ePROM group. Analysis of median overall survival after 2 years of follow up reported that significant survival benefit persisted [22.5 months A clinician has to decide whether further contact is needed. Red: Definite need of contact or the patient asks for a consultation.

• Of 8256 telePRObased contacts from epilepsy outpatients, up to 48% were handled without further contact.

• For sleep apnoea up to 57% of the 1424 telePRObased contacts did not require further contact.

• Completion rates were over 90% at baseline and follow up.

AE, adverse event; AMTRA, ambulatory monitoring of cancer therapy using an interactive application; BPSS, breast cancer patient support system; CI, confidence interval; CT, computerized tomography; CTCAE, common terminology criteria for adverse events; DAS28, disease activity score in 28 joints; ED, emergency department; EORTC QLQ-C30, European organisation for research and treatment of cancer quality of life questionnaire C30; EPR, electronic patient records; ePRO, electronic patient-reported outcome; ER, emergency room; FACT-PWB, functional assessment of cancer therapy scale-general physical well-being subscale; HADS, hospital anxiety and depression scale; HR, hazard ratio; HRQOL, health-related quality of life; IMPROVED, improving management of patient-reported outcomes via electronic data; MSAS, memorial symptom assessment scale; NCI-CTCAE, National Cancer Institute's common terminology criteria for adverse events; PFS, progression free survival (defined as the duration from randomisation to the first radiologic observation of disease progression or to last follow up when the patient is censored); PRO, patient-reported outcome; PROMIS, patient reported outcome measure information system; RA, rheumatoid arthritis; RCT, randomised controlled trial; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; STAR, symptom tracking and reporting; US, United States. Table 2 .

Critical appraisal of included studies. Handa et al. 38 RCT

It was unclear what constituted usual care and whether the materials provided to the non-ePROM group was also given to ePROM group. Was the assignment of participants to interventions randomised? 3. Were all participants who entered the study accounted for at its conclusion? 4. Were the people analysing outcomes 'blinded'?* (due to the nature of the intervention, patient or investigator blinding was impossible) 5. Were the study groups similar at the start of the randomised controlled trial? 6. Apart from the experimental intervention, did each study group receive the same level of care (that is, were they treated equally)? 7. Were the effects of intervention reported comprehensively? 8. Was the precision of the estimate of the intervention or treatment effect reported? 9. Do the benefits of the experimental intervention outweigh the harms and costs? CASP, critical appraisal skills programme; CI, confidence interval; ePROM, electronic patient-reported outcomes measures; FACT-L, Functional Assessment of Cancer Therapy-Lung; RCT, randomised controlled trial. However, these results must be interpreted with caution. Survival benefits may be age-dependent, as demonstrated by the results of a secondary analysis by Basch et al. 28, 29, 42 This analysis reported a significantly lower risk of emergency room visits and improved survival among younger patients with solid tumours (median age = 58 years, range 26-69 years) whose symptoms were managed electronically in addition to receiving usual care. 42 These benefits were not observed among older patients who were managed electronically in addition to usual care (median age = 75 years, range 70-91 years). 42 Efficient utilisation of healthcare resources ePROM systems provide medical teams with the opportunity to interact with patients and deliver care efficiently. Changes in patients' clinical status can be monitored remotely and hospital appointments reserved for those that require inperson assessment. Therefore, the use of ePROMs in the routine care of patients with chronic diseases could lead to a more efficient utilisation of limited healthcare resources. In Denmark, the use of a generic ePROM system, Ambuflex, is being used routinely to manage patients across nine chronic conditions (epilepsy, coronary heart disease, narcolepsy, sleep apnoea, prostate cancer, asthma, rheumatoid arthritis, colorectal cancer and kidney failure) to facilitate clinical decisionmaking. 24 Patients complete ePROMs remotely and their data is used to determine whether they require an outpatient hospital appointment. The use of the Ambuflex system led to decreases of 48% and 57% in hospital follow-up visits in patients with epilepsy and sleep apnoea, respectively. 27 The use of this ePROM system across the chronic conditions also led to reductions in (a) the reimbursement of patient transportation costs and (b) the need to destroy excess chemotherapy drugs for the oncology patients (which might have been due to better treatment adherence).

The previously mentioned study that utilised the STAR ePROM system also reported benefits related to resource utilisation. 28 After a year of follow up, patients in the STAR arm had significantly fewer emergency department (ED) visits compared with those who received usual care (34% versus 41%). 28 This effect was more pronounced when the computer-inexperienced subgroups of the two study arms were compared directly (34% versus 56%). The study also reported a significant reduction in hospitalisation among the computer-inexperienced subgroup of the STAR arm (44% versus 63%) but not in the computer-experienced subgroup. 28 Conversely, in the United Kingdom (UK), the RCT of the eRAPID system by Absolom et al. did not find any significant difference in the utilisation of healthcare resources between the intervention and control arms. 33 Specifically, there were no significant differences in chemotherapy delivery, hospital admissions, acute oncology assessments or emergency hotline calls. 33 Improved symptom management An RCT conducted in Sweden evaluated the utility of an interactive 'Interaktor' ePROM app for delivering treatment-related symptom management versus usual care for patients with breast cancer receiving chemotherapy. 37 Patients in the Interaktor group experienced nausea, vomiting, sadness, loss of appetite and constipation less frequently. 37 Overall physical symptom distress was significantly lower and emotional functioning significantly improved in the Interaktor group (see Table 1 ). 37 De Thurah et al. conducted an RCT comparing disease activity control for rheumatic arthritis using the AmbuFlex system with usual outpatient follow-up care by physicians. Patients with low disease activity who used AmbuFlex experienced similar levels of disease activity control compared with those who received conventional outpatient follow up. 31 Furthermore, aside from the fixed yearly outpatient visits, patients randomised to AmbuFlex required fewer extra visits per year (see Table 1 ). 31 Based on functional assessment of cancer therapy-general, physical well-being subscale (FACT-PWB) data, there was better symptom control among patients undergoing chemotherapy in the intervention arm of the eRAPID RCT at 6 (p = 0.028) and 12 (p = 0.039) weeks. 33 However, no significant difference was recorded at 18 weeks between the two arms of the study (p = 0.699). 33 journals.sagepub.com/home/taj 15

Mooney et al. evaluated the efficacy of an automated symptom management system in patients commencing chemotherapy in an RCT. 41 All the patients reported their chemotherapy-related symptoms using the system but patients in the symptom care at home (SCH) arm received selfmanagement information and nurse practitioners acted on alerts of poorly controlled symptoms following decision support guidance. 41 At the end of the follow-up period, symptom severity across all symptoms was significantly less in patients randomised to the SCH arm compared with usual care (p < 0.001).

An analysis of PROMs and physician-reported outcomes data, collected as part of an RCT comparing two hypofractionated radiotherapy schedules, was conducted by Rammant et al. 46 The study found poor concordance between patient and physician reported side effects with physicians significantly underrecognising and underreporting patients' symptom burden. 46 Handa et al. conducted an RCT to evaluate the effectiveness of a smartphone-based application to track treatment side effects of patients undergoing chemotherapy. 38 In addition to measuring physical symptoms, the application measured changes in patients' anxiety and depression levels using the hospital anxiety and depression scale (HADS). The study found that medical staff underestimated the severity of 25% of patients' physical symptoms and the most frequently underestimated were muscle/joint pain, fatigue, and nausea. Symptom monitoring in this study did not lead to significant improvements in patients' HADS scores.

The studies by Rammant and Handa confirm previous findings that medical teams underestimate symptoms compared with patient reports. 47, 48 They also highlight the need for a mechanism, such as ePROMs, by which patients can provide assessments of their health status to complement clinician assessments.

In an RCT conducted by Kroenke et al., patients who screened positive for at least one SPADE (sleep, pain, anxiety, depression and low energy/ fatigue) symptom were recruited (their underlying chronic conditions were unspecified). 40 They completed the five matching domains of the patient reported outcome measure information system (PROMIS) profile-29 electronically and were subsequently randomised to a feedback group in which their clinician only received a visual display of their symptom scores or a control group in which the scores were not provided to clinicians. 40 At the end of the 3-month follow-up period, while both groups had moderate symptom improvement, there was a non-significant trend favouring the feedback compared with the control group (see Table 1 ). 40 There is a possibility that participants in the RCTs by Handa and Kroenke did not experience a significant improvement in their symptoms because there were no specific interventions to address issues highlighted by the ePROM systems. 38, 40, 49 While this might be acceptable for an RCT, depending on the study design and aims, collecting and analysing PROM data in a routine setting without acting on the information by providing treatment/support for problems identified could be a waste of resources. 49 Kroenke et al. concluded that providing clinicians ePROM data without additional systems support or incentives is insufficient. 40 Medical teams need to carefully consider how ePROMs data will be translated into actionable plans for patient management when developing ePROM systems.

A multi-centre, non-randomised prospective cohort analysis performed in Belgium compared ePROMs collection using a web-based system (AMTRA) with usual care among patients with solid tumours undergoing chemotherapy. 43 Patients in the intervention arm used an application to provide daily reports of the severity of their symptoms. 43 They were allowed to provide additional reports if required. Self-care information was provided for mild or moderate symptoms, and alerts were sent to the medical staff in cases of severe adverse events. Patients experienced a statistically significant reduction of mean severity grade for nausea, constipation, loss of appetite, fatigue and dyspnea over the follow-up period. 43 The AMTRA app uniquely incorporated a treatment adherence aid that required patients to log their medication intake. An automatic reminder was sent to the provider if an entry was not logged and followed up within 24 h if there was still no response. There was a median treatment adherence rate of 98.7% in the 44 patients receiving oral chemotherapy. 43 The study's success may also be attributed to the training that was provided to patients and medical staff prior to study commencement. Medical staff received training on the system and the pathways for responding to patientgenerated alerts. 43 Patients had home visits during which they were shown how to use the application by trainers who emphasised the importance of reporting symptoms and adhering to treatment.

The COVID-19 pandemic has emphasised the need and relevance of ePROMs in clinical trials and routine practice. 50 There is now a renewed interest in all forms of telemedicine and the effect will probably remain even after the threat of COVID-19 has subsided.

When the COVID-19 epidemic began, it quickly became apparent that providing medical care outside hospital settings reduced the risk of exposure to, and transmission of, the SARS-CoV-2 virus for patients and clinicians. 50 Kricke et al. recently reported early findings from the implementation of an outpatient COVID-19 monitoring program in the US. Over 6000 patients with presumed COVID-19 infection completed an electronic daily symptom questionnaire from home and were stratified based on symptom severity. While the majority of the patients did not require hospitalisation, remote monitoring led to emergency department referrals for an average of nine patients per day. 39 With the growing incidence of long COVID, the use of ePROMs for symptom monitoring could facilitate the identification of life-threatening complications that may develop later in patients.

While the studies included in this review demonstrate potential benefits of using ePROMs in patient care, there are a number of challenges that need to be adequately addressed to ensure seamless implementation and integration of ePROMs into a health system. 51

The use of ePROMs could precipitate patients' experiences of survey fatigue, which may lead to a steady decline in survey completion over time. 52 Other individual and system level factors which may be associated with reduced propensity to complete surveys or to higher survey fatigue, include: older age, disease severity, the presence of comorbidities, 11 questionnaire length and item relevance, and perceptions of response burden. 53 Participant fatigue may be minimised with innovative PROM assessment methods. For instance, computerised adaptive testing (CAT), an algorithm-based method, tailors ePROMs to the individual by automatically selecting and sequentially administering the most relevant items (questions) from an item bank based on a respondent's prior responses. [54] [55] [56] With the expansion of ePROMs, the expansion of CATs and other methods to improve survey design and reduce survey burden should be considered. 57, 58 The AmbuFlex system attributed its high completion rates to the use of a mixed-mode (paper and web) method of data collection. 27 A recent publication by Niels Hjollund reflected on the 15-year use of the AmbuFlex system for the follow-up of patients with chronic diseases. He noted that although a mixed-mode method of collection of PROM data was initially implemented to maximise response rates (66.5% of responses were paper-based in 2005), there has been a gradual preference for an electronic option (only 4.3% were paper-based in 2019). 59 Despite a decline from an initial baseline completion rate of 94%, Taarnhoj et al. still reported relatively high completion rates of more than 70% over six cycles of chemo-or immunotherapy. The rates only declined after patients had received the sixth cycle of treatment. 60 In the study by Kricke et al., 20% of patients monitored for COVID-19 symptoms did not fill out the daily questionnaire, particularly those with mild symptoms. 39 Missing data is also a common problem with patientreported data. Identifying causes of missing entries could improve the clinical utility of ePROMs and highlight opportunities to improve ePROM completion. 61 The level of health literacy among patients may significantly influence their decisions to engage with ePROM interventions. 62 To encourage compliance, efforts need to be made to ensure that patients understand the importance and potential benefits of providing ePROM data in relation to their clinical management and health outcomes.

journals.sagepub.com/home/taj 17

The issues of cost and cost-effectiveness could significantly influence the decision by health care providers to commission the development and implementation of ePROM systems. For policymakers, the cost and cost-effectiveness of ePROM interventions in comparison with existing follow up care may determine whether crucial governmental and/or institutional support in terms of legislation or finance is secured.

Data from a recent trial compared the cost-effectiveness of usual care, tele-rehabilitation, and tele-rehabilitation plus pharmacological pain management for patients with late-stage cancer (details about cancer types not provided). 63 At the $100,000.00 willingness-to-pay threshold, the tele-rehabilitation model was the most costeffective strategy in 95% of simulations. 63 The authors attributed the cost savings to the fact that patients in the tele-rehabilitation arms were less likely to require intensive care unit admission. 63 Cost-effectiveness analysis was pre-specified as a secondary outcome in an RCT by Denis et al. 35 An awareness of the tensions and challenges experienced by HCPs with ePROMs and their engagement and involvement in ePROM system development, implementation and integration is essential to overcome these barriers. 11, [66] [67] [68] 70, 71 Clear guidelines or actionable plans are essential to enable clinicians respond confidently and effectively to ePROM data. 38, 40, 41, 49 Integration of ePROMs into existing health systems The successful integration of ePROM into existing health systems and workflows has the potential to transform clinical practice. 72 This process may be complex, resource-intensive, requiring an iterative approach and stakeholder involvement. 51, 70, [72] [73] [74] [75] Appropriate training of HCPs to handle and respond to ePROM data needs to be provided in order to facilitate integration with existing clinical workflows. 43, 66, 76 LeRouge et al. have recently published a comprehensive toolkit to facilitate the process of implementation and integration of ePROMs with existing health systems. 77 This toolkit comprises of guidelines that focus on the various aspects of the process including ePROM integration approaches, workflow designing, leveraging of health ICT, and display of data. 77

There is growing evidence that the thoughtful incorporation of ePROMs into health systems could have meaningful and positive impacts on clinical outcomes. However, most of this evidence to support their use originates from the field of oncology. Thus, there is a need to demonstrate its potential impact in other chronic conditions. Initial work is underway to explore the use of ePROMs in the routine care of patients with CKD. The RePROM study is currently being conducted by researchers and clinicians based at the Centre for Patient-Reported Outcomes Research at the University of Birmingham and the Queen Elizabeth Hospital Birmingham within the UK National Health Service University Hospitals Birmingham Foundation Trust (UHBFT). 78 The study will determine the feasibility of undertaking a full-scale RCT of ePROMs in the symptom monitoring of patients living with advanced CKD. 78 A pilot study also involving patients with CKD at the University Health Network, Toronto, Canada, will test the feasibility of implementing an ePROM toolkit to assess physical and emotional symptoms, using the PROMIS CATs. This is linked to a symptom management, self-management support resource hub. 79, 80 The Evaluation of Routinely Measured Patientreported Outcomes in Haemodialysis Care (EMPATHY) RCT, which aims to determine the effects of routine measurement of ePROMs on the experiences of patients undergoing in-centre haemodialysis in Alberta and Ontario, Canada, is currently underway. 81 The use of ePROMs in the management of patients receiving home dialysis is also being trialled in the ePRO Kidney study. 82

There is increasing evidence that the use of ePROMs could have significant impacts on outcomes valued by patients, healthcare providers and researchers. While our paper focusses primarily on quantifiable effects of ePROMs on traditional clinical outcomes, this does not mean that other outcomes are less important. 83 As most of the evidence we found was derived from oncology, there is an urgent need for similar work in other subspecialties that care for medically complex patients. ePROM systems that demonstrate maximum clinical utility and minimum patient burden need to be seamlessly integrated into a learning health system. Whilst the development and implementation of these systems may be initially costly and resource-intensive, patient preferences and existing evidence to support their implementation suggests the need for continued research prioritisation in this area. In addition, there is a need for case studies to demonstrate best practices for achieving and maintaining patient and HCP engagement. Finally, further research is required to demonstrate the long-term cost-effectiveness of using ePROMs in routine clinical practice. Significant work remains, but the implementation of ePROMs provides a valuable opportunity to transform the quality and delivery of care for medically complex patients.

OLA has received personal fees from Gilead Sciences Ltd, Merck and GSK outside the submitted work. All other authors declare that they have no competing interests. generic integrated PRO system, WestChronic. Interact J Med Res 2014; 3: e5.

Telemedicine: a guide to assessing telecommunications in health care

Transforming gastroenterology care with telemedicine

An external validation of models to predict the onset of chronic kidney disease using population-based electronic health records from Salford

Key methodological considerations for usability testing of electronic patient-reported outcome (ePRO) systems

Electronic patient-reported outcomes: the time is ripe for integration into patient care and clinical research

Capturing patient-reported outcome (PRO) data electronically: the past, present, and promise of ePRO measurement in clinical trials

National Center for Chronic Disease Prevention and Health Promotion

A patient-centred approach to measuring quality in kidney care: patient-reported outcome measures and patient-reported experience measures

Brief communication: patient satisfaction with the use of tablet computers: a pilot study in two outpatient home dialysis clinics

Preferences for use and design of electronic patient-reported outcomes in patients with chronic obstructive pulmonary disease

Patient and clinician perspectives on electronic patientreported outcome measures in the management of advanced CKD: a qualitative study

Patient and clinician opinions of patient reported outcome measures (PROMs) in the management of patients with rare diseases: a qualitative study

Strategies to use tablet computers for collection of electronic patient-reported outcomes

How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis

Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial

Relational use of an electronic quality of life and practice support system in hospital palliative consult care: a pilot study

Provision of feedback on perceived health status to health care professionals: a systematic review of its impact

The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature

Does providing feedback on patient-reported outcomes to healthcare professionals result in better outcomes for patients? A systematic review

Computerized quality-of-life screening in a cancer pain clinic

Comparative pilot study of symptoms and quality of life in cancer patients and patients with end stage renal disease

Electronic patient-reported outcome systems in oncology clinical practice

Feasibility and acceptance of electronic quality of life assessment in general practice: an implementation study

Use of patient-reported outcome (PRO) measures at group and patient levels: experiences from the

Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension

Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension

AmbuFlex: tele-patient-reported outcomes (telePRO) as the basis for follow-up in chronic and malignant diseases

Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial

Overall survival results of a trial assessing patientreported outcomes for symptom monitoring during routine cancer treatment

Tele-health followup strategy for tight control of disease activity in rheumatoid arthritis: results of a randomized controlled trial

Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer

Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy

Improving survival in patients treated for a lung cancer using self-evaluated symptoms reported through a web application

Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients

Twoyear survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer

Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer -a randomized controlled trial

Effectiveness of a smartphone application as a support tool for patients undergoing breast cancer chemotherapy: a randomized controlled trial

Rapid implementation of an outpatient Covid-19 monitoring program. NEJM Catal Innov Care Deliv. Epub ahead of print 16

Incorporating PROMIS symptom measures into primary care practice-a randomized clinical trial

Automated home monitoring and management of patientreported symptoms during chemotherapy: results of the symptom care at home RCT

Differential effects of an electronic symptom monitoring intervention based on the age of patients with advanced cancer

AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients

Common terminology criteria for adverse events (CTCAE) version 5.0

Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)

Patient-versus physician-reported outcomes

Agreement between patient-reported symptoms and their documentation in the medical record

Renal provider recognition of symptoms in patients on maintenance hemodialysis

Symptom improvement requires more than screening and feedback

Patient-reported outcomes: central to the management of COVID-19

Implementing the learning health system: from concept to action

Prospective trial on telemonitoring of geriatric cancer patients using handheld devices

Perceptions of response burden associated with completion of patient-reported outcome assessments in oncology

Utilizing multidimensional computer adaptive testing to mitigate burden with patient reported outcomes

Use of computerized adaptive testing to develop more concise patient-reported outcome measures

Expanding the patient's voice in nephrology with patient-reported outcomes

Latent variable mixture models: a promising approach for the validation of patient reported outcomes

Adjusting for cross-cultural differences in computer-adaptive tests of quality of life

Fifteen years' use of patientreported outcome measures at the group and patient levels: trend analysis

Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy -a feasibility study

An analysis of missing items in real-world electronic patient reported outcomes data: implications for clinical care

Health literacy: a necessity for increasing participation in health care

Cost-effectiveness of the Collaborative Care to Preserve Performance in Cancer (COPE) trial tele-rehabilitation interventions for patients with advanced cancers

Costeffectiveness of web-based patient-reported outcome surveillance in patients with lung cancer

Cost-effectiveness of symptom monitoring with patient-reported outcomes during routine cancer treatment

Divergent perspectives on the use of the edmonton symptom assessment system (revised) in palliative care

Micro-meso-macro practice tensions in using patient-reported outcome and experience measures in hospital palliative care

Design and introduction of a quality of life assessment and practice support system: perspectives from palliative care settings

What are the attitudes of health professionals regarding patient reported outcome measures (PROMs) in oncology practice? A mixed-method synthesis of the qualitative evidence

Using stakeholder engagement to overcome barriers to implementing patient-reported outcomes (PROs) in cancer care delivery: approaches from 3 prospective studies

Provider perspectives on the integration of patient-reported outcomes in an electronic health record

User's guide to implementing patient-reported outcomes assessment in clinical practice

Engaging patients and clinicians in online reporting of adverse effects during chemotherapy for cancer the eRAPID system (electronic patient selfreporting of adverse events: patient information and aDvice)

Implementation and early adaptation of patientreported outcome measures into an electronic health record: a technical report

Developing an implementation strategy for systematic measurement of patient-reported outcomes at an academic health center

Training clinicians in how to use patient-reported outcome measures in routine clinical practice

ePROs in clinical care: guidelines and tools for health systems

Development of an electronic patient-reported outcome measure (ePROM) system to aid the management of patients with advanced chronic kidney disease

Exploring the use of tablet computer-based electronic data capture system to assess patient reported measures among patients with chronic kidney disease: a pilot study

A study of patient-reported distress measures

A cluster randomized controlled trial for the Evaluation of routinely Measured PATient reported outcomes in HemodialYsis care (EMPATHY): a study protocol

Electronic patient-reported outcomes in clinical kidney practice (ePRO Kidney)

Psychosocial distress and health service utilization in patients undergoing hemodialysis: a prospective study

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: OLA is supported by the National This paper represents independent research. The views expressed are those of the author and not necessarily those of the NIHR BRC West Midlands, the University of Birmingham or any funding institutions.

Olalekan Lee Aiyegbusi https://orcid.org/0000